article thumbnail

Opinion: STAT+: There’s a better way to get drugs on the market: progressive approval

STAT

The public and pharmaceutical companies are calling for changes in drug regulation and the costs of medicines. Companies want to see products approved faster for financial reasons, and patients want medicines that can improve their lives. They are right to do so.

article thumbnail

Pharmaceutical training boost: how the growth and skills levy could shape industry development

European Pharmaceutical Review

While this investment led to a seven percent rise in annual apprenticeship starts within the life sciences sector between 2018/19 and 2022/23, industry leaders have consistently argued that the narrow focus on apprenticeships left gaps in training provision. billion in 2017/18 to 2.5 billion in 2023/24.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

STAT

German pharmaceutical company Bayer is expanding its U.S. Bayer’s C-suite has been on a soul-searching mission for the last year, spurred by new leadership and the realization that the company is, as new CEO Bill Anderson said earlier this month, “ badly broken.

article thumbnail

STAT+: U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer

STAT

Pharmaceutical companies in the U.K. Between 2004 to 2021, the Prescription Medicines Code of Practice Authority, a self-regulatory body overseen by the Association of the British Pharmaceutical Industry, ruled on more than 1,100 cases involving nearly 160 companies where there was a breach of the industry code.

article thumbnail

Chemo-free regimen demonstrates efficacy in NSCLC

European Pharmaceutical Review

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

article thumbnail

NICE recommends first licenced treatment for AL amyloidosis

European Pharmaceutical Review

According to the Janssen Pharmaceutical Companies of Johnson & Johnson and NICE, DVCd is recommended for the rare bone marrow disorder, only if daratumumab is stopped after 24 cycles of treatment, or earlier if the condition progresses.

article thumbnail

AI will continue to attract investment in near future in the healthcare industry

Pharmaceutical Technology

In the next two years, the surveyed healthcare industry professionals believed that their companies will prioritise AI as the main investment target (figure 2).